Last reviewed · How we verify

NCT05911750: PAPIMALE

Prevalence and Clinical Implications of HPV Infection in Male IBD Patients

Recruiting now Last updated 12 September 2025
What this trial tests

trial testing Anal pap smear and oral swab for cytology and HPV testing in HPV Infection in 384 participants. Currently enrolling.

Timeline
12 February 2023
Primary endpoint
31 January 2026
1 June 2026

Quick facts

Lead sponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment384
Start date12 February 2023
Primary completion31 January 2026
Estimated completion1 June 2026
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Who can join

Adults 18 to 79, male only, with HPV Infection or Dysplasia Anus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims at describing the prevalence of Human Papillomavirus (HPV) infection in anal and oral samples of men with Inflammatory Bowel Disease (IBD) and detecting risk factors for the infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for HPV Infection

Currently open trials in the same condition.

Other Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05911750.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing